Clarivate sees FY25 adjusted EPS 60c-70c, consensus 73c

Sees FY25 revenue $2.28B-$2.4B, consensus $2.55B. Sees FY25 adjusted EBITDA $940M-$1B. Sees FY25 free cash flow $300M-$380M. “Our 2025 outlook includes the disposal of specific Academia & Government and Life Sciences & Healthcare transactional products, which are expected to be completed by the end of 2026,” said Jonathan Collins, executive VP and CFO. “We currently expect recurring organic revenues to be flat, at the mid-point in 2025. We will continue to aggressively manage our cost structure and currently expect a balanced approach to capital allocation in 2025.”